Pathomechanism of Adverse Reactions to Biological Treatment of Inflammatory Skin Conditions

被引:0
|
作者
Li, Lichen [1 ,2 ]
Naisbitt, Dean J. [3 ]
Sun, Yonghu [1 ,2 ]
Zhang, Furen [1 ,2 ]
机构
[1] Shandong First Med Univ, Hosp Skin Dis, Jinan, Shandong, Peoples R China
[2] Shandong Acad Med Sci, Shandong Prov Inst Dermatol & Venereol, Jinan, Shandong, Peoples R China
[3] Univ Liverpool, MRC Ctr Drug Safety Sci, Dept Mol & Clin Pharmacol, Liverpool, England
基金
中国国家自然科学基金;
关键词
adverse drug reactions; biological agents; inflammatory dermatoses; HYPERSENSITIVITY REACTIONS; DUPILUMAB TREATMENT; IGE ANTIBODIES; IN-VITRO; RITUXIMAB; SECUKINUMAB; INFLIXIMAB; PSORIASIS; THERAPY; IMMUNOGENICITY;
D O I
10.1111/cea.14583
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Biological agents are widely used across medicine, including for immune-mediated skin conditions such as psoriasis and atopic dermatitis. When used to treat a relevant pathological process, they demonstrate impressive efficacy and credible safety, helping to achieve remission and improved function and quality of life. However, with their expanded use, awareness and understanding of adverse reactions to biologicals have also increased. Herein, we discuss the pathomechanism of adverse reactions to biological agents used to treat skin conditions and apply these to Pichler's classification system. This classification differentiates five distinct types, namely overstimulation (type alpha), hypersensitivity or immunogenicity (beta), immunodeviation (gamma), cross-reactivity (delta) and nonimmunologic adverse reactions (epsilon). This classification covers most types of adverse reactions associated with use of biological agents and could be used to better understand the reaction pathogenesis and manage the clinical features of biological adverse effects. Biological agents have been widely applied in dermatology, and their adverse side effects can be classified into five types (alpha-epsilon) according to their pathomechanism. A greater understanding of reaction mechanisms will enhance (i) categorisation of adverse events to biological agents and (ii) our ability to manage patients. Abbreviations: PsO, psoriasis; AD, atopic dermatitis; BP, bullous pemphigoid; AA, alopecia areata. *Created with image
引用
收藏
页码:973 / 983
页数:11
相关论文
共 50 条
  • [21] Response to COVID-19 Vaccination in Patients with Inflammatory Bowel Disease on Biological Treatment
    Bodini, Giorgia
    Giuliana, Elisabetta
    Giberti, Irene
    Guarona, Giulia
    Benvenuto, Federica
    Ferretti, Elisa
    Demarzo, Maria Giulia
    Da Rin, Giorgio
    Icardi, Giancarlo
    Giannini, Edoardo G.
    GASTROINTESTINAL DISORDERS, 2022, 4 (02): : 77 - 83
  • [22] Adverse reactions during biological drug therapy in psoriasis: clinical series and a review of the literature
    Montesu, M. A.
    Addis, G. M.
    Satta, R.
    Cottoni, F.
    GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA, 2011, 146 (04): : 273 - 281
  • [23] Adverse skin reactions induced by BRAF inhibitors: A systematic review
    Sibaud, V.
    Lamant, L.
    Maisongrosse, V.
    Delord, J. -P.
    ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2013, 140 (8-9): : 510 - 520
  • [24] Bioactivation of drugs in the skin: relationship to cutaneous adverse drug reactions
    Sharma, Amy M.
    Uetrecht, Jack
    DRUG METABOLISM REVIEWS, 2014, 46 (01) : 1 - 18
  • [25] Apigenin: A Therapeutic Agent for Treatment of Skin Inflammatory Diseases and Cancer
    Yoon, Ji Hye
    Kim, Mi-Yeon
    Cho, Jae Youl
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (02)
  • [26] An In Vitro Human Skin Test for Predicting Skin Sensitization and Adverse Immune Reactions to Biologics
    Ahmed, Shaheda Sameena
    Ahmed, Mohammed Mahid
    Ishaq, Abbas
    Freer, Matthew
    Stebbings, Richard
    Dickinson, Anne Mary
    TOXICS, 2024, 12 (06)
  • [27] Pimecrolimus for the treatment of inflammatory skin disease
    Wolff, K
    Stuetz, A
    EXPERT OPINION ON PHARMACOTHERAPY, 2004, 5 (03) : 643 - 655
  • [28] Dermpath and Clinic: How to manage adverse reactions to biological agents
    Lefevre, Marine-Alexia
    Nosbaum, Audrey
    EUROPEAN JOURNAL OF DERMATOLOGY, 2021, 31 (03) : 426 - 427
  • [29] Must immunomodulators be added to biological treatment in inflammatory bowel disease?
    Gomollon, Fernando
    Gisbert, Javier P.
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2010, 33 (01): : 43 - 53
  • [30] Treatment of adverse drug reactions in a dermatology department
    Ganeva, Maria
    Gancheva, Tanya
    Baldaranov, Ivan
    Troeva, Jeni
    Hristakieva, Evgenya
    CENTRAL EUROPEAN JOURNAL OF MEDICINE, 2011, 6 (01): : 37 - 44